Abstract:OBJECTIVE:To assess the clinical equivalence of TQ-Z2301, a biosimilar of adalimumab, to the reference adalimumab in the treatment of Chinese patients with active ankylosing spondylitis.METHODS:This multicenter, randomized, double-blind, positive-controlled phase III clinical trial was conducted in 19 centers across China. Chinese adults with active ankylosing spondylitis despite being treated with non-steroidal anti-inflammatory drugs for ≥ 4 weeks were randomized in a 1:1 ratio to subcutaneously receive 40 mg of TQ-Z2301 or adalimumab every other week for 24 weeks. The primary endpoint was the percentage of patients who achieved at least 20% improvement according to the Assessment of Spondyloarthritis International Society criteria (ASAS20) at week 24. The equivalence was established if the 90% CI for RR of ASAS20 between two groups at week 24 fell within (0.80, 1.25). Secondary endpoints included efficacy measures of disease activity, spinal mobility, physical function and quality of life, immunogenicity, and pharmacokinetic parameters. Safety analysis was done for all patients who received at least one study drug.RESULTS:A total of 380 patients were enrolled in the study between September 2018 and October 2019, including 188 in the TQ-Z2301 group and 192 in the adalimumab group. In the full analysis population, the ASAS20 response rate at week 24 was 86.70% in the TQ-Z2301 group, and 80.73% in the adalimumab group, the RR of ASAS20 for TQ-Z2301 versus adalimumab was 1.074, 90% CI (0.997, 1.157), fell within the predefined equivalence boundary (0.80, 1.25). Except for the SF-36 at week 12, there was no statistical difference between the two groups for all the secondary endpoints (P>0.05). The incidence of adverse events group was 82.45% in the TQ-Z2301, and 83.85% in the adalimumab group, the safety profile of the two groups was similar. The profiles of immunogenicity and pharmacokinetics were also similar between the two groups.CONCLUSION:TQ-Z2301 is equivalent to adalimumab for the treatment of Chinese patients with active ankylosing spondylitis. The safety, immunogenicity, and pharmacokinetic characteristics of both drugs are similar.TRIAL REGISTRATION:The study (CTR20181863) was registered in the Chinese Clinical Trial Registry on 19 October 2018. Key Points • TQ-Z2301 showed the equivalence of efficacy compared with the reference adalimumab for the treatment of Chinese patients with active ankylosing spondylitis. • The safety, immunogenicity, and pharmacokinetics profiles of TQZ-2301 were similar to those of the reference adalimumab.

Efficacy of Yishen Juanbi Oill on Ankylosing Spondylitis

Efficacy and safety of TNF-α inhibitors for active ankylosing spondylitis patients: Multiple treatment comparisons in a network meta-analysis

Combined Bushen Qiangdu Recipe and sulfasalazine treatment reduced cytokine levels and improved the symptoms of ankylosing spondylitis

Vitamin D in Ankylosing Spondylitis: Review and Meta-Analysis

ObserVation of warm acupuncture combined with Chinese medicine fumigation in the treatment for actiVity mandatory spondylitis

Comparison of the Efficacy and Safety of the Adalimumab Biosimilar TQ-Z2301 and Adalimumab for the Treatment of Chinese Patients with Active Ankylosing Spondylitis: a Multi-Center, Randomized, Double-Blind, Phase III Clinical Trial

Meta-analysis of Duhuo Jisheng Decoction Combined with Chemical Medicines in the Treatment of Anky-losing Spondylitis

The Effectiveness and Safety of Yi Shen Juan Bi Pill on Rheumatoid Arthritis: a Protocol for Systematic Review and/or Meta-Analysis

Consensus of Chinese Orthopaedic Experts on Diagnosis and Treatment of Ankylosing Spondylitis.

Short-Term Efficacy and Safety of Secukinumab for Ankylosing Spondylitis: A Systematic Review and Meta-Analysis of RCTs

Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis

Changes in Efficacy Indicators for Adalimumab Biosimilar Candidate (HS016) for the Treatment of Active Ankylosing Spondylitis at Various Time Points

Safety and Efficacy of Prefilled Liquid Etanercept-Biosimilar Yisaipu for Active Ankylosing Spondylitis: A Multi-Center Phase III Trial

Clinical Research of 45 Ankylosing Spondylitis Treated with Integrated Chinese and Western Medicine

The efficacy and safety of mesalazine in the treatment o f inflammatory bowel disease--A nationwide multicenter clinical trial

Efficacy and Safety of AK111, in Patients with Active Ankylosing Spondylitis: Results from a Randomized, Double-Blind, Placebo-Controlled, Phase II Clinical Study

Clinical Study on Erteng Tongbi Mixture Plus Zhengqing Fengtongning Sustained Released Tablet in the Treatment of Rheumatoid Arthritis:A Report of 30 Cases

Evaluation of Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis Based on a Health Survey: Sub-Analysis of a Phase 3 Study

[Effect on ankylosing spondylitis at early-middle stage and bone marrow edema of sacroiliac joint treated with acupuncture and governor vessel moxibustion]

Clinical study on long-term effectiveness of leflunomide compared with sulfasalazine in treatment of ankylosing spondylitis

Yi Shen Juan Bi Pill alleviates bone destruction in inflammatory arthritis under postmenopausal conditions by regulating ephrinB2 signaling